BerGenBio ASA - New share capital registered

08 Dec 2023 08:33 CET

Bergen 8 December 2023 - Reference is made to the stock exchange announcement by
BerGenBio ASA (the "Company") on 30 November 2023 regarding the final results of
the first exercise period for the warrants ("Warrants") issued in connection
with the rights issue, which resulted in an allocation of 68,156,682 new shares
in the Company ("New Shares") to investors holding Warrants.

The share capital increase pertaining to the New Shares is now registered with
the Norwegian Register of Business Enterprises. After this, the Company's new
registered share capital is NOK 268,868,921.40 divided into 2,688,689,214
shares, each with a nominal value of NOK 0.10.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com



Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com



About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections. BerGenBio is based in Bergen, Norway with a
subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange
(ticker: BGBIO). For more information, visit?www.bergenbio.com

This information is published in accordance with the requirements of the Oslo
Rule Book II and is subject to the disclosure requirements pursuant to Section 5
-12 of the Norwegian Securities Trading Act.

More information:
Access the news on Oslo Bors NewsWeb site